Circulating tumor DNA (ctDNA) testing is rapidly emerging as a powerful tool to detect minimal residual disease (MRD), guide treatment decisions, and potentially transform breast cancer care across the disease continuum, according to Jason…
Increasingly Specific ctDNA Assays Are Set to Define the Future of Breast Oncology
